Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Pfizer/Hospira's Biosimilar Pipeline: Substantial Overlap, Limited Divestiture So Far

This article was originally published in The Pink Sheet Daily

Executive Summary

All five biosimilars in Pfizer’s clinical pipeline overlap with those in Hospira’s, but even though only infliximab is required to be divested, the others could also be sold off to reach cost-saving targets.

You may also be interested in...



Pfizer Not Making Pricing Changes, Sees Ways To Work With Trump

Pfizer CEO Ian Read said during the company’s quarterly call that there are ‘lots of ways’ to work with the new Trump administration, his comments coming on the same day several industry leaders met with the new US president.

Pfizer's Herceptin Biosimilar Moving Forward Amid Rising Competition

Pfizer hopes positive top-line Phase III trial data on its Herceptin (trastuzumab) biosimilar can help it tap the lucrative market in HER2-overexpressing cancers, but analysts say that therapeutic space looks increasingly crowded with no clear favorite yet in sight.

Pfizer's Herceptin Biosimilar Moving Forward Amid Rising Competition

Pfizer hopes positive top-line Phase III trial data on its Herceptin (trastuzumab) biosimilar can help it tap the lucrative market in HER2-overexpressing cancers, but analysts say that therapeutic space looks increasingly crowded with no clear favorite yet in sight.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

PS078974

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel